Form 4: Rocket Pharmaceuticals Director Receives 30,000 RSU Grant

Mikael Dolsten, a Director at Rocket Pharmaceuticals, Inc., was granted 30,000 restricted stock units (RSUs) on June 18, 2025, which will vest in full on June 18, 2026.

Summary

• Mikael Dolsten, a Director of Rocket Pharmaceuticals, Inc. (RCKT), acquired 30,000 shares in the form of Restricted Stock Units (RSUs) on June 18, 2025.
• The RSUs were acquired at a price of $0 per unit, which is typical for equity compensation grants.
• Following this transaction, Mikael Dolsten directly beneficially owns a total of 44,220 shares of common stock.
• The newly acquired 30,000 RSUs are set to vest in full on June 18, 2026.
• Existing holdings include 14,220 RSUs that convert to common stock on a one-for-one basis and are scheduled to cliff vest on December 31, 2025.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally a positive signal, indicating continued alignment of management's interests with shareholders and a commitment to the company's future. It is a routine compensation event and not indicative of immediate financial distress or exceptional performance.

Positives

• The grant of 30,000 RSUs to a Director aligns management's interests with shareholder value, as the value of the RSUs is tied to the company's stock performance.
• Equity compensation is a common method to incentivize and retain key personnel, indicating continued commitment from the Director.

Risks

• The value of the RSU grant is dependent on the future stock price of Rocket Pharmaceuticals, Inc., meaning the actual realized value could be lower if the stock price declines before vesting.
• Dilution risk exists for existing shareholders as RSUs convert to common stock upon vesting, increasing the total number of outstanding shares.

Future Outlook

The newly granted 30,000 Restricted Stock Units (RSUs) are scheduled to vest in full on June 18, 2026, indicating a future conversion of these units into common stock. Additionally, 14,220 previously held RSUs are set to vest on December 31, 2025.

Industry Context

This RSU grant is a standard form of equity compensation in the biotechnology and pharmaceutical industries, used to align the interests of directors and executives with the long-term performance of the company. It reflects ongoing compensation practices within the sector.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) at a $0 exercise price is a common practice for equity compensation across the biotechnology and pharmaceutical sectors, similar to compensation structures observed at companies like Sarepta Therapeutics or BioMarin Pharmaceutical, where executive and director compensation often includes significant equity components tied to future performance and retention.
• The vesting schedule, with a cliff vest after approximately one year for the new grant and a shorter period for existing units, is within the typical range for RSU grants designed to incentivize long-term commitment and performance, comparable to vesting schedules seen at peer companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the Director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value. However, it also introduces a minor dilutive effect upon vesting.
• Employees: This transaction is specific to a director's compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• The 30,000 RSUs granted on June 18, 2025, are expected to vest in full on June 18, 2026.
• The 14,220 previously held RSUs are expected to cliff vest on December 31, 2025.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Mikael Dolsten, Restricted Stock Units, RSU grant, insider transaction, equity compensation, SEC Form 4, director compensation, stock vesting